3652 results for «231»

Filter By

3652 results

TAVI in a patient with heavily calcified valve anatomy - LIVE case

18 Feb 2023 – From PCR Tokyo Valves 2023

An 80-year-old male with chronic kidney disease and interstitial pneumonia treated under steroids presented a symptomatic severe aortic stenosis with massive calcifications on the valves and only on the valves (not the LVOT).
Watch the operators implant a Sapien 3 23 mm (-1cc) with a predilatation (Balloon...

TAVI in a patient with heavily calcified valve anatomy

Future devices and techniques

19 Feb 2023 – From PCR Tokyo Valves 2023

In this session, find out more about TMVR device options and trial updates, a case of severe mitral regurgitation treated with TMVR, ongoing trials and future innovations regarding transcatheter tricuspid valve repair and replacement, and much more!

Future devices and techniques

My worst nightmare in TAVI

Listen to our experts share their most nightmarish TAVI cases and follow the debate around their treatments. For instance, would you make the same choices when faced with a 76-year-old female patient diagnosed as severe AS, transferred for SAVR/TAVI, who got a new Abif and cardiogenic...

My worst nightmare in TAVI

PCR Tokyo Valves 2023 Closing Ceremony

19 Feb 2023 – From PCR Tokyo Valves 2023

This closing ceremony of the 2023 edition of the PCR Tokyo Valves is the occasion to unveil the results of the best abstract and best case competitions and to congratulate the finalists. It is also the moment to take stock of this excellent edition, to thank...

PCR Tokyo Valves 2023 Closing Ceremony

TAVI in small annulus and coronary artery disease - Session with LIVE case

19 Feb 2023 – From PCR Tokyo Valves 2023

Watch the complex case of an 84-year-old woman with hypertension, type 2 diabetes and coronary artery disease who presented with worsening NYHA class II-III exertional dyspnoea, but no angina, and find out how she was treated LIVE.

TAVI in small annulus and CAD

The optimal first valve choice for all patients with aortic stenosis

18 Feb 2023 – From PCR Tokyo Valves 2023

How have advances in TAVI impacted the lifetime journey of patients with aortic stenosis? Join this panel of experts as they discuss the importance of optimizing the first procedure and the key issues regarding treatment options in patients with bioprosthetic valve deterioration of transcatheter heart valve.

The optimal first valve

How to optimise the lifetime management of TAVI patients with long-life expectancy?

18 Feb 2023 – From PCR Tokyo Valves 2023

This session addresses three essential elements of a successful TAVI procedure: the impact of valve design on long-term durability, how to mitigate the risk of paravalvular leakage, and the importance of the possibility for coronary access after TAVI.

How to optimise the lifetime

Remaining unmet needs and strategies in TAVI

19 Feb 2023 – From PCR Tokyo Valves 2023

This session focuses on valve design and durability performance in TAVI for patients with aortic stenosis, and the way it impacts future patient outcomes. 

Remaining unmet needs

PCR Tokyo Valves 2026: Your travel guide featuring upcoming exclusive booking services and special deals.

Join us in Tokyo from 13-15 February: Explore the Toranomon Hills Tower venue and stay updated on the best deals for flights and hotel accommodations.

Percutaneous or surgical management of post-infarction ventricular septal defects: The United Kingdom National Registry

17 Sep 2022

Elad Asher provides his take on the UK National Registry which was presented at the TCT congress 2022 by Joel Peter Giblett on behalf of the UK PIVSD investigators.

Elad Asher

Author

Elad Asher
Percutaneous or Surgical Management of Post-Infarction Ventricular Septal Defects: The United Kingdom National Registry

OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease

04 Nov 2021

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG

EuroPCR 2026 – Long-term mortality following revascularisation for left main disease

20 May 2026

Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is a meta-analysis of long-term data from 4 randomised trials investigating...

EuroPCR 2026 – Long-term mortality following revascularisation for left main disease
Didn’t find what you were looking for?